Friday, 21 Feb 2020

You are here

Gilead Submits Filgotinib NDA to the FDA

Gilead has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for filgotinib, an investigational, oral, selective JAK1 inhibitor for the treatment of adults who are living with moderate-to-severe rheumatoid arthritis (RA).

The NDA is the first step in trying to gain FDA approval of a new drug.  The company says that a priority review voucher was submitted with the NDA, hoping this will shorten the anticipated time for review.

The filing is supported by 52-week data from the global Phase 3 FINCH clinical program, which evaluated the efficacy and safety of filgotinib in 3,452 patients with moderate to severely active RA.

In the FINCH studies, filgotinib met its primary endpoints, demonstrating efficacy and safety results in multiple RA patient populations, including patients with:

  • Prior inadequate response to methotrexate treatment (MTX)
  • Those who intolerant to one or more biologic treatments; and
  • MTX treatment-naïve patients.

Safety results were consistent across the trials and further reinforce the long-term safety and tolerability profile of filgotinib for a broad range of RA patients.

 

 

Earlier this year, filgotinib was submitted for regulatory approval from the European Medicines Agency and Japanese Ministry of Health, Labor and Welfare.

Filgotinib is an investigational agent and is not approved by any regulatory authority. Its efficacy and safety have not been established.

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Tofacitinib Effective in Refractory Still's Disease

Fourteen cases reported from mainland China suggest that tofacitinib (TOFA) may be effective in patients with refractory adult-onset Still’s disease (AOSD), further adding to a growing list of potential use of JAK inhibition in managing inflammatory, and now autoinflammatory, disease.

QD Clinic - Hepatitis B and Biologics

QD Clinic - Lessons from the clinic Active HBV infection (HGsAg+) on anti-viral therapy but needs a biologic - what should you use?

Biosimilars for Rheum Disease: Failure to Launch

The availability of biologic biosimilars has thus far had negligible impact on prescribing practices in the United States, in stark contrast to what has been observed in some European countries, researchers reported.

Best of 2019 - Is Methotrexate Necessary with Tofacitinib?

Rheumatoid arthritis patients taking tofacitinib (Xeljanz) plus methotrexate who achieved low disease activity (LDA) may be able to withdraw from the latter agent without significant worsening of disease activity, a researcher reported at EULAR 2019 in Madrid.

Best of 2019 - Ups and Downs with Abatacept

Two recent studies have examined the effect of starting abatacept upon the risk of serious hospitalized infections or cancer, showing divergent results from claims data analyses.